Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: A comparison between multiparameter flow cytometry and Wilm's tumor 1 levels

Annals of Hematology

Volumn 93, Issue 7, 2014, Pages 1149-1157

  Rossi, Giovanni ^a   Minervini, Maria Marta ^a   Melillo, Lorella ^a   Di Nardo, Francesco ^b   De Waure, Chiara ^b   Scalzulli, Potito Rosario ^a   Perla, Gianni ^a   Valente, Daniela ^a   Sinisi, Nicola ^a   Cascavilla, Nicola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute myeloid leukemia; Log clearance; Minimal residual disease; Multiparameter flow cytometry; WT1 RNA

Indexed keywords

CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMIA REMISSION; LOG CLEARANCE; MALE; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENES, WILMS TUMOR; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; WILMS TUMOR; YOUNG ADULT;

EID: 84902657421     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2029-9     Document Type: Article

References (38)

1. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National Cancer Research Institute Adult Leukaemia Working Group (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365
2. Mrozek K, Bloomfield CD (2006) Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2006:169-177
3. Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, de Lange D, Boeckx N, Hählen K, Reinhardt D, Creutzig U, Schuurhuis GJ, Zwaan CM, Kaspers GJ (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20:1217-1220 (Pubitemid 43905824)
4. Chou WC, Hou HA, Liu CY, Chen CY, Lin LI, Huang YN, Chao YC, Hsu CA, Huang CF, Tien HF (2011) Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Ann Oncol 22:696-704
5. Schiller J, Praulich I, Krings Rocha C, Kreuzer KA (2012) Patientspecific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia. Eur J Haematol 89:53-62
6. Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E, Mellert G, Hiddemann W, Spiekermann K (2009) Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 144:517-523
7. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acutemyeloid leukemia study group. J Clin Oncol 29:2709-2716
8. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S (2005) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416-1423 (Pubitemid 41148947)
9. Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P (2004) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acutemyeloid leukaemia patients - results from a single-centre study. Br J Haematol 125:590-600 (Pubitemid 38747961)
10. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be useful tool for monitoringminimal residual disease in acute leukemia patients. Leukemia 16:2115-2121
11. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Scnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VHJ, Ommen H, Preudhomme C, Saglio G, Grimwade D (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27:5195-5201
12. Garg M, Moore H, Tobal K, Liu Yin JA (2003) Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123:49-59 (Pubitemid 37222757)
13. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Ho Kim E, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698-1704 (Pubitemid 36237562)
14. Alonso-Dominguez JM, Tenorio M, Velasco D, Abalo L, Lozano S, Villarrubia J, López-Jimenez J, Grande S, Ayala R (2012) Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet 205:190-191
15. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96:3948-3952
16. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, Orfao A(2001) Early immunophenotypical evaluation ofminimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746-1751
17. Buccisano F,Maurillo L, Gattei V,Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo Coco F, Amadori S, Venditti A (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20:1783-1789 (Pubitemid 44590961)
18. Al-Mawali A, Gillis D, Lewis I (2009) The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 76B:91-101
19. Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T (2004) Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 89:528-540 (Pubitemid 38691239)
20. Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L, D'Arena G, Zini G, Cascavilla N (2012) Comparison between flow cytometry and WT1 RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res 36(4):401-406
21. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, Andreansky M, Behm FG, Raimondi SC, Shurtleff SA, Downing JR, Campana D (2003) Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123:243-252 (Pubitemid 37305058)
22. Hourigan CS, Karp JE (2013) Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 10(8):460-471. doi:10.1038/nrclinonc.2013.100
23. Rossi G, Nomdedeu JF, Minervini MM, Fontana A, Garcia-Dabrio MC, Cascavilla N (2013) CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease. Eur J Haematol 90(2):171-174
24. van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM (2009) Standardization of flow cytometry in myelodisplastic syndromes. Report from the first European LeukemiaNet working conference on flow cytometry in myelodisplastic syndromes. Haematologica 94(8):1124-1134
25. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T (2004) Determination of relapse risk based on assessment of minimal residual disease in unselected patients with acute myeloid leukemia. Blood 104:3078-3085 (Pubitemid 39517010)
26. Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, Li A (2012) Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol 21:225-233
27. Arellano M, Pakkala S, Langston A, Tighiouart M, Pan L, Chen Z, Heffner LT, Lonial S,Winton E, Khoury HJ (2012) Early clearance of peripheral blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer 118:5278-5282
28. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, Vey N, Casasnovas O,Witz F, BénéMC (2009) Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 23(2):350-357
29. Gianfaldoni G, Mannelli F, Baccini M, Antonioli E, Leoni F, Bosi A (2006) Clearance of leukemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukemia: a pilot study. Br J Haematol 134:54-57 (Pubitemid 43830027)
30. Cheson BD, Bennett JM, Kopecky KJ, Büchner T,Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis (2003) Revised recommendations of response Criteria. Treatments outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649 (Pubitemid 46594039)
31. Olaru D, Campos L, Flandrin P, Nadal N,Duval A, Chautard S, Guyotat D (2008) Multiparametric analysis of normal and postchemotherapy bone marrow: implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 74B:17-24
32. Al-Mawali A, Gillis D, Hissaria P, Lewis I (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 129:934-945
33. Van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz MG, Malec M, Langerak AW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13:1901-1928
34. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, Roti G, Rosati R, Martelli MF, Diverio D, Lo Coco F, Biondi A, Saglio G, Mecucci C, Falini B (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20:1103-1108 (Pubitemid 43797304)
35. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 Worlds Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important change. Blood 114:937-951
36. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai JL, Ballerini P,Mazingue F, Fasola S, Dehée A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J (2006) High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515 (Pubitemid 46638771)
37. Lasa A, Carricondo M, Estivill C, Bussaglia E, Gich I, Brunet S, Aventin A, Sierra J, Nomdedéu JF (2009) WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 33:1643-1649
38. Nomdedeu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J (2013) Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia 27(11):2157-2164